Press Releases Ascendis Pharma A/S

Equities

ASND

US04351P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
130.4 ^USD	+0.75%		+7.67%	+3.54%

May. 22	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
May. 16	Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascendis Pharma A/S : Form 6-K	May. 16	PU
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism	May. 14	AQ
ECE 2024: 2-year results from the Phase 3 PaTHway Trial	May. 14	PU
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial	May. 13	AQ
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024	May. 09	AQ
Ascendis Pharma A/S : Form 6-K	May. 02	PU
Ascendis Pharma Reports First Quarter 2024 Financial Results	May. 02	AQ
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024	Apr. 25	AQ
Ascendis Pharma - United Kingdom's MHRA Approves YORVIPATH in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 25	AQ
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 24	AQ
Ascendis Pharma A/S : Form 6-K	Apr. 10	PU
Ascendis Pharma A/S : Form 6-K	Mar. 27	PU
Ascendis Pharma A/S : Form 6-K	Mar. 14	PU
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024	Mar. 04	AQ
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results	Feb. 07	AQ
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 07	AQ
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024	Jan. 31	AQ
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism	Jan. 31	AQ
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors	Jan. 29	AQ
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey	Jan. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ascendis Pharma A/S

Equities

ASND

US04351P1012

Press Releases

Filters